Pancreatic Cancer pp 1015-1034 | Cite as

Pathological Reporting and Staging Following Pancreatic Cancer Resection

  • Irene Esposito
  • Diana Born
Reference work entry


The clinical management of cancer relies on robust pathological data for the assessment of the extent of the disease, in order to plan the best care for the individual patient. Although general guidelines for the handling and pathology reporting of pancreatic specimens exist and are constantly updated by professional pathology committees, no uniform and widely accepted standardized protocol for the examination of pancreatic surgical specimens is currently available. In particular, there is no consensus regarding the definition of the relevant margins of the surgical specimens and the definition of microscopic residual disease. This is reflected in the discrepancy between the high rates of local recurrence of pancreatic cancer and the reported curative resection rates. In this chapter the potential causes for this lack of standardization in the pathology reporting for pancreatic cancer are discussed and a possible consensus protocol for the specimens’ dissection, which also takes into account the biological characteristics of this extraordinary aggressive neoplasm, is presented.


Pancreatic Cancer Pancreatic Ductal Adenocarcinoma Bile Duct Carcinoma Retrieve Lymph Node Resection Margin Status 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Sobin L, Wittekind C: TNM Classification of Malignant Tumours, 6th ed. New York: Wiley, 2002.Google Scholar
  2. 2.
    Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M: AJCC Cancer Staging Manual, 6th ed. Berlin: Springer, 2002.CrossRefGoogle Scholar
  3. 3.
    Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon MF, Quirke P: Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994;344:707–711.CrossRefPubMedGoogle Scholar
  4. 4.
    Quirke P, Durdey P, Dixon MF, Williams NS: Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986;2:996–999.CrossRefPubMedGoogle Scholar
  5. 5.
    Autschbach F: The pathological assessment of total mesorectal excision: what are the relevant resection margins? Recent Results Cancer Res 2005;165:30–39.CrossRefPubMedGoogle Scholar
  6. 6.
    Hermanek P, Hermanek P, Hohenberger W, Klimpfinger M, Kockerling F, Papadopoulos T: The pathological assessment of mesorectal excision: implications for further treatment and quality management. Int J Colorectal Dis 2003;18:335–841.PubMedGoogle Scholar
  7. 7.
    Cabioglu N, Hunt KK, Sahin AA, Kuerer HM, Babiera GV, Singletary SE, Whitman GJ, Ross MI, Ames FC, Feig BW, Buchholz TA, Meric-Bernstam F: Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol 2007;14:1458–1471.CrossRefPubMedGoogle Scholar
  8. 8.
    Gage I, Schnitt SJ, Nixon AJ, Silver B, Recht A, Troyan SL, Eberlein T, Love SM, Gelman R, Harris JR, Connolly JL: Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer 1996;78:1921–1928.CrossRefPubMedGoogle Scholar
  9. 9.
    Olson TP, Harter J, Munoz A, Mahvi DM, Breslin T: Frozen section analysis for intraoperative margin assessment during breast-conserving surgery results in low rates of re-excision and local recurrence. Ann Surg Oncol 2007;14:2953–2960.CrossRefPubMedGoogle Scholar
  10. 10.
    Smitt MC, Nowels KW, Zdeblick MJ, Jeffrey S, Carlson RW, Stockdale FE, Goffinet DR: The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer 1995;76:259–267.CrossRefPubMedGoogle Scholar
  11. 11.
    Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Buchler MW: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758–768.CrossRefPubMedGoogle Scholar
  12. 12.
    Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M: Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003;27:324–329.CrossRefPubMedGoogle Scholar
  13. 13.
    Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586–594.CrossRefPubMedGoogle Scholar
  14. 14.
    Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC: Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993;217:144–148.CrossRefPubMedGoogle Scholar
  15. 15.
    Cameron JL, Riall TS, Coleman J, Belcher KA: One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10–15.CrossRefPubMedGoogle Scholar
  16. 16.
    Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, Schirmacher P, Buchler MW: Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008;15:1651–1660.CrossRefPubMedGoogle Scholar
  17. 17.
    Kuhlmann K, de Castro S, van Heek T, Busch O, van Gulik T, Obertop H, Gouma D: Microscopically incomplete resection offers acceptable palliation in pancreatic cancer. Surgery 2006;139:188–196.CrossRefPubMedGoogle Scholar
  18. 18.
    Nagakawa T, Nagamori M, Futakami F, Tsukioka Y, Kayahara M, Ohta T, Ueno K, Miyazaki I: Results of extensive surgery for pancreatic carcinoma. Cancer 1996;77:640–645.CrossRefPubMedGoogle Scholar
  19. 19.
    Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210.CrossRefPubMedGoogle Scholar
  20. 20.
    Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB: Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007;246:52–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A: Redefining the R1 resection in pancreatic cancer. Br J Surg 2006;93:1232–1237.CrossRefPubMedGoogle Scholar
  22. 22.
    Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ: 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199–1210; discussion 210–211.CrossRefPubMedGoogle Scholar
  23. 23.
    Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248–257; discussion 57–60.CrossRefPubMedGoogle Scholar
  24. 24.
    Ujiki MB, Talamonti MS: Guidelines for the surgical management of pancreatic adenocarcinoma. Semin Oncol 2007;34:311–320.CrossRefPubMedGoogle Scholar
  25. 25.
    Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S: Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006;10:511–518.CrossRefPubMedGoogle Scholar
  26. 26.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics. CA Cancer J Clin 2007;57:43–66.CrossRefPubMedGoogle Scholar
  27. 27.
    Verbeke CS: Resection margins and R1 rates in pancreatic cancer – are we there yet? Histopathology 2008;52:787–796.CrossRefPubMedGoogle Scholar
  28. 28.
    Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005;54:385–357.CrossRefPubMedGoogle Scholar
  29. 29.
    Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE: Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128–1137.CrossRefPubMedGoogle Scholar
  30. 30.
    Kleeff J, Michalski CW, Friess H, Buchler MW: Surgical treatment of pancreatic cancer: the role of adjuvant and multimodal therapies. Eur J Surg Oncol 2007;33:817–823.PubMedGoogle Scholar
  31. 31.
    Staley CA, Cleary KR, Abbruzzese JL, Lee JE, Ames FC, Fenoglio CJ, Evans DB: The need for standardized pathologic staging of pancreaticoduodenectomy specimens. Pancreas 1996;12:373–380.CrossRefPubMedGoogle Scholar
  32. 32.
    Cubilla AL, Fitzgerald PJ: Tumors of the exocrine pancreas. In WH Hartmann, LH Sobin (eds.). AFIP Atlas of tumor pathology, 2nd series, fascicle 19, Washington, DC: Armed Forces Institute of Pathology, 1982.Google Scholar
  33. 33.
    Klöppel G: Pathology of nonendocrine pancreatic tumors. In VLW Go, et al. (ed.). The pancreas, 2nd edition. New York: Raven Press; 1993.Google Scholar
  34. 34.
    Luttges J, Zamboni G, Kloppel G: Recommendation for the examination of pancreaticoduodenectomy specimens removed from patients with carcinoma of the exocrine pancreas. A proposal for a standardized pathological staging of pancreaticoduodenectomy specimens including a checklist. Dig Surg 1999;16:291–296.CrossRefPubMedGoogle Scholar
  35. 35.
    Solcia E, Capella C, Klöppel G: Tumors of the pancreas. In J Rosai, L Sobin (eds.). AFIP Atlas of tumor pathology, 3rd series, Fascicle 20. Washington, DC: Armed Forces Institute of Pathology, 1997.Google Scholar
  36. 36.
    Henne-Bruns D, Vogel I, Luttges J, Kloppel G, Kremer B: Ductal adenocarcinoma of the pancreas head: survival after regional versus extended lymphadenectomy. Hepatogastroenterology 1998;45:855–866.PubMedGoogle Scholar
  37. 37.
    Luttges J, Vogel I, Menke M, Henne-Bruns D, Kremer B, Kloppel G: The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch 1998;433:237–242.CrossRefPubMedGoogle Scholar
  38. 38.
    Kloppel G, Hruban RH, Longnecker DS: Ductal adenocarcinoma of the pancreas. In SR Hamilton, LA Aaltonen, (eds.) WHO Classification of Tumors: Pathology and Genetics of Tumors of the Digestive System. Lyon: IARC Press, 2000, pp. 221–230.Google Scholar
  39. 39.
    Japan Pancreas Society: Classification of Pancreatic Carcinoma. 2nd English ed. Tokyo: Kanehara & Co.; 2003.Google Scholar
  40. 40.
    Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 2004;28:219–230.CrossRefPubMedGoogle Scholar
  41. 41.
    Erkan M, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I, Giese T, Buchler MW, Giese NA, Friess H: Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 2007;132:1447–1464.CrossRefPubMedGoogle Scholar
  42. 42.
    Esposito I, Penzel R, Chaib-Harrireche M, Barcena U, Bergmann F, Riedl S, Kayed H, Giese N, Kleeff J, Friess H, Schirmacher P: Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 2006;208:673–685.CrossRefPubMedGoogle Scholar
  43. 43.
    Kleeff J, Beckhove P, Esposito I, Herzig S, Huber PE, Lohr JM, Friess H: Pancreatic cancer microenvironment. Int J Cancer 2007;121:699–705.CrossRefPubMedGoogle Scholar
  44. 44.
    Tsuchiya R, Noda T, Harada N, Miyamoto T, Tomioka T, Yamamoto K, Yamaguchi T, Izawa K, Tsunoda T, Yoshino R, et al. Collective review of small carcinomas of the pancreas. Ann Surg 1986;203:77–81.CrossRefPubMedGoogle Scholar
  45. 45.
    Khalifa MA: Intraoperative assessment of the Whipple resection specimen. J Clin Pathol 2007;60:975–980.CrossRefPubMedGoogle Scholar
  46. 46.
    Nagtegaal ID, Marijnen CA, Kranenbarg EK, van de Velde CJ, van Krieken JH: Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002;26:350–357.CrossRefPubMedGoogle Scholar
  47. 47.
    Quirke P, Dixon MF: The prediction of local recurrence in rectal adenocarcinoma by histopathological examination. Int J Colorectal Dis 1988;3:127–131.CrossRefPubMedGoogle Scholar
  48. 48.
    Albores-Saavedra J, Heffess C, Hruban RH, Klimstra D, Longnecker D: Recommendations for the reporting of pancreatic specimens containing malignant tumors. The Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol 1999;111:304–307.PubMedGoogle Scholar
  49. 49.
    Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, Biankin SA, Compton C, Fukushima N, Furukawa T, Goggins M, Kato Y, Kloppel G, Longnecker DS, Luttges J, Maitra A, Offerhaus GJ, Shimizu M, Yonezawa S: An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004;28:977–987.CrossRefPubMedGoogle Scholar
  50. 50.
    Berger AC, Watson JC, Ross EA, Hoffmann JP: The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004;70:235–240; discussion 240.PubMedGoogle Scholar
  51. 51.
    Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, Wolfgang C, Hruban RH, Schulick RD, Yeo CJ, Choti MA: Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141:610–618. Epub 2007 Mar 23.CrossRefPubMedGoogle Scholar
  52. 52.
    Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, Choti MA, Pawlik TM: Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008;15:165–174. Epub 2007 Sep 26.CrossRefPubMedGoogle Scholar
  53. 53.
    Smith RA, Bosonnet L, Ghaneh P, Raraty M, Sutton R, Campbell F, Neoptolemos JP: Preoperative CA19–9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 2008; 25:226–232.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Irene Esposito
    • 1
    • 3
  • Diana Born
    • 2
  1. 1.Institute of Pathology, Helmholtz Zentrum MünchenMunichGermany
  2. 2.Institute of PathologyTechnische Universität MünchenMunichGermany
  3. 3.Institute of Pathology, InselspitalUniversity of Bern Switzerland

Personalised recommendations